Boston Scientific To Acquire Silk Road Medical For $1.16B In Cash, Offering $44 Per Share; 30% Premium Over Last Closing Price; Deal To Enhance Neurovascular Portfolio And Close By Q4 2024 Pending Regulatory Approvals

6/20/24 1:21:31 PM ET

$BSX

$SILK

Medical/Dental Instruments

Health Care

Medical/Dental Instruments

Health Care

Get the next $BSX alert in real time by email

Boston Scientific To Acquire Silk Road Medical For $1.16B In Cash, Offering $44 Per Share; 30% Premium Over Last Closing Price; Deal To Enhance Neurovascular Portfolio And Close By Q4 2024 Pending Regulatory Approvals

Get the next $BSX alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$BSX
$SILK

Company	Date	Price Target	Rating	Analyst
Boston Scientific Corporation $BSX	10/18/2024		Buy → Hold	Needham
Silk Road Medical Inc. $SILK	7/11/2024		Buy → Sell	Argus
Boston Scientific Corporation $BSX	5/30/2024	$90.00	Buy	Goldman
Silk Road Medical Inc. $SILK	3/7/2024	$24.00	Hold → Buy	Argus
Boston Scientific Corporation $BSX	2/1/2024	$65.00 → $80.00	Neutral → Buy	Mizuho
Silk Road Medical Inc. $SILK	1/19/2024	$9.00 → $20.00	Hold → Buy	Stifel
Silk Road Medical Inc. $SILK	1/3/2024	$20.00	Buy	Lake Street
Silk Road Medical Inc. $SILK	10/24/2023		Underperform → Peer Perform	Wolfe Research

More analyst ratings

$BSX
$SILK
Leadership Updates

Live Leadership Updates

Silk Road Medical Names Chas McKhann Chief Executive Officer
SUNNYVALE, Calif., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Silk Road Medical, Inc. (NASDAQ:SILK) ("Silk Road" or the "Company"), a company focused on reducing the risk of stroke and its devastating impact, today announced that Chas McKhann has been appointed Chief Executive Officer (CEO), effective immediately. Mr. McKhann is an accomplished leader with more than 25 years of experience in the medical device industry, including C-suite positions at seven public and private companies. Most recently, Mr. McKhann served as President and CEO of Apollo Endosurgery (acquired by Boston Scientific in April 2023), where he created and led a transformational growth strategy for the company's minimal
11/2/23 8:00:00 AM ET
$SILK
Medical/Dental Instruments
Health Care
Silk Road Medical Announces Retirement of CEO Erica Rogers
Working with Leading Executive Search Firm to Identify Successor SUNNYVALE, Calif., Oct. 10, 2023 (GLOBE NEWSWIRE) -- Silk Road Medical, Inc. (NASDAQ:SILK), a company focused on reducing the risk of stroke and its devastating impact, today announced that CEO Erica Rogers plans to retire from the Company following the completion of a succession process. The Company is working with Spencer Stuart, a leading executive search firm. To ensure a smooth transition, Ms. Rogers will remain as President and CEO of the Company until her successor is appointed. "I'd like to thank Erica for her tremendous contributions to Silk Road over the last 11 years. Erica has been integral in leading and expand
10/10/23 4:20:00 PM ET
$SILK
Medical/Dental Instruments
Health Care
CVS Health appoints Michael F. Mahoney to its Board of Directors
WOONSOCKET, R.I., Sept. 21, 2023 /PRNewswire/ -- CVS Health Corporation (NYSE:CVS) has appointed Michael F. Mahoney, Chairman and CEO of Boston Scientific Corporation (NYSE:BSX), a global medical technology leader, to serve on the Board of Directors (the "Board") of CVS Health, effective November 1. "Mike's focus throughout his career – to drive improvements in health outcomes and increase access to care – align with our mission at CVS Health," said CVS Health President and CEO Karen S. Lynch. "Adding a well-respected health care leader to our Board demonstrates our continued
9/21/23 6:45:00 AM ET
$BSX
$CVS
Medical/Dental Instruments
Health Care
Retail-Drug Stores and Proprietary Stores
Consumer Staples

Boston Scientific to Participate in the 2024 UBS Global Healthcare Conference
MARLBOROUGH, Mass., Nov. 5, 2024 /PRNewswire/ -- Boston Scientific Corporation (NYSE:BSX) will participate in the 2024 UBS Global Healthcare Conference on Tuesday, November 12, 2024. Nick Spadea-Anello, president, Electrophysiology, and Jon Monson, senior vice president, Investor Relations, will participate in a 35-minute question-and-answer session with the host analyst at approximately 7:15 a.m. PT / 10:15 a.m. ET. A live webcast and replay of the session will be accessible at htts://investors.bostonscientific.com. The replay will be available approximately one hour followin
11/5/24 8:00:00 AM ET
$BSX
Medical/Dental Instruments
Health Care
Boston Scientific Announces Agreement to Acquire Cortex, Inc.
Acquisition to complement electrophysiology portfolio with solution to advance the treatment of complex atrial fibrillation MARLBOROUGH, Mass., Nov. 4, 2024 /PRNewswire/ -- Boston Scientific Corporation (NYSE:BSX) today announced it has entered into a definitive agreement to acquire Cortex, Inc., an Ajax Health company. Cortex is a privately held medical technology company focused on the development of a diagnostic mapping solution which may identify triggers and drivers outside of the pulmonary veins that are foundational to atrial fibrillation (AF), a heart rhythm disorder affecting nearly 38 million people globally.1
11/4/24 6:55:00 AM ET
$BSX
Medical/Dental Instruments
Health Care
ACURATE neo2™ Aortic Valve System Data Presented at Late-Breaking Clinical Trial Session at TCT 2024
MARLBOROUGH, Mass. and WASHINGTON, Oct. 30, 2024 /PRNewswire/ -- Boston Scientific Corporation (NYSE:BSX) today announced the results of the primary endpoint of the ACURATE IDE clinical trial, which evaluated the ACURATE neo2™ Aortic Valve System in the treatment of patients with severe, symptomatic aortic stenosis at low, intermediate, high and extreme risk of open-heart surgery. The data were presented as a late-breaking clinical trial at Transcatheter Cardiovascular Therapeutics® (TCT®) 2024, the annual scientific symposium of the Cardiovascular Research Foundation® (CRF®).
10/30/24 11:41:00 AM ET
$BSX
Medical/Dental Instruments
Health Care

Boston Scientific Announces Results for Third Quarter 2024
MARLBOROUGH, Mass., Oct. 23, 2024 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) generated net sales of $4.209 billion during the third quarter of 2024, growing 19.4 percent on a reported basis, 19.5 percent on an operational1 basis and 18.2 percent on an organic2 basis, all compared to the prior year period. The company reported GAAP net income attributable to Boston Scientific common stockholders of $469 million or $0.32 per share (EPS), compared to $505 million or $0.34 per share a year ago, and achieved adjusted3 EPS of $0.63 for the period, compared to $0.50 a year ago.
10/23/24 6:30:00 AM ET
$BSX
$SILK
Medical/Dental Instruments
Health Care
Boston Scientific Announces Conference Call Discussing Third Quarter 2024 Results
-Company to also host virtual webcast with a cardiology business update- MARLBOROUGH, Mass., Oct. 2, 2024 /PRNewswire/ -- Boston Scientific Corporation (NYSE:BSX) will webcast its conference call discussing financial results and business highlights for the third quarter ended September 30, 2024, on Wednesday, October 23, 2024, at 8:00 a.m. ET. The call will be hosted by Mike Mahoney, chairman and chief executive officer, and Dan Brennan, executive vice president and chief financial officer. The company will issue a news release announcing financial results for the third quarter on October 23 prior to the conference call.
10/2/24 8:00:00 AM ET
$BSX
Medical/Dental Instruments
Health Care
Boston Scientific Announces Results for Second Quarter 2024
MARLBOROUGH, Mass., July 24, 2024 /PRNewswire/ -- Boston Scientific Corporation (NYSE:BSX) generated net sales of $4.120 billion during the second quarter of 2024, growing 14.5 percent on a reported basis, 16.1 percent on an operational1 basis and 14.7 percent on an organic2 basis, all compared to the prior year period. The company reported GAAP net income attributable to Boston Scientific common stockholders of $324 million or $0.22 per share (EPS), compared to $261 million or $0.18 per share a year ago, and achieved adjusted3 EPS of $0.62 for the period, compared to $0.53 a year ago.
7/24/24 6:30:00 AM ET
$BSX
$SILK
Medical/Dental Instruments
Health Care

Boston Scientific To Acquire Silk Road Medical For $1.16B In Cash, Offering $44 Per Share; 30% Premium Over Last Closing Price; Deal To Enhance Neurovascular Portfolio And Close By Q4 2024 Pending Regulatory Approvals

Chat with this insight

Recent Analyst Ratings for $BSX$SILK

$BSX$SILK SEC Filings

Boston Scientific Corporation filed SEC Form 8-K: Regulation FD Disclosure

SEC Form 10-Q filed by Boston Scientific Corporation

Boston Scientific Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

$BSX$SILK Leadership Updates

Live Leadership Updates

Silk Road Medical Names Chas McKhann Chief Executive Officer

Silk Road Medical Announces Retirement of CEO Erica Rogers

CVS Health appoints Michael F. Mahoney to its Board of Directors

$BSX$SILK Market Insights

Live Market Insights

Apple To Rally Around 10%? Here Are 10 Top Analyst Forecasts For Thursday

JP Morgan Maintains Overweight on Boston Scientific, Raises Price Target to $85

Canaccord Genuity Maintains Buy on Boston Scientific, Raises Price Target to $88

$BSX$SILK Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

Ballinger Kevin J. bought $198,783 worth of shares (11,700 units at $16.99), increasing direct ownership by 192% to 17,807 units (SEC Form 4)

$BSX$SILK FDA approvals

Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

$BSX$SILK Large Ownership Changes

This live feed shows all institutional transactions in real time.

$BSX$SILK Press Releases

Fastest customizable press release news feed in the world

March 1, 2024 - FDA Roundup: March 1, 2024

Amendment: SEC Form SC 13D/A filed by Silk Road Medical Inc.

SEC Form SC 13D filed by Silk Road Medical Inc.

Amendment: SEC Form SC 13G/A filed by Silk Road Medical Inc.

Boston Scientific to Participate in the 2024 UBS Global Healthcare Conference

Boston Scientific Announces Agreement to Acquire Cortex, Inc.

ACURATE neo2™ Aortic Valve System Data Presented at Late-Breaking Clinical Trial Session at TCT 2024

$BSX$SILK Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Chairman, President & CEO Mahoney Michael F exercised 111,887 shares at a strike of $16.79 and sold $13,794,851 worth of shares (162,778 units at $84.75), decreasing direct ownership by 3% to 1,521,205 units (SEC Form 4)

EVP, Human Resources Carruthers Wendy sold $588,876 worth of shares (6,983 units at $84.33) and exercised 4,263 shares at a strike of $19.31, decreasing direct ownership by 8% to 32,028 units (SEC Form 4)

EVP & Group Pres, Cardiology Fitzgerald Joseph Michael exercised 116,639 shares at a strike of $21.07 and sold $11,264,888 worth of shares (132,527 units at $85.00), decreasing direct ownership by 9% to 160,467 units (SEC Form 4)

$BSX$SILK Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

$BSX$SILK Financials

Live finance-specific insights

Boston Scientific downgraded by Needham

Silk Road Medical downgraded by Argus

Goldman initiated coverage on Boston Scientific with a new price target

Boston Scientific Announces Results for Third Quarter 2024

Boston Scientific Announces Conference Call Discussing Third Quarter 2024 Results

Boston Scientific Announces Results for Second Quarter 2024

Recent Analyst Ratings for
$BSX
$SILK

$BSX
$SILK
SEC Filings

$BSX
$SILK
Leadership Updates

$BSX
$SILK
Market Insights

$BSX
$SILK
Insider Purchases

$BSX
$SILK
FDA approvals

$BSX
$SILK
Large Ownership Changes

$BSX
$SILK
Press Releases

$BSX
$SILK
Insider Trading

$BSX
$SILK
Analyst Ratings

$BSX
$SILK
Financials